Washington University School of Medicine in St. Louis | Strategic Alliance Partners

Brian A. Van Tine, MD, PhD, discusses the methods utilized in the phase 2 Spearhead 1 trial evaluating afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Brian A. Van Tine, MD, PhD, sheds light on the promise of SPEAR T-cell therapy in patients with synovial sarcoma and MRCLS, the safety and efficacy observed with afami-cel in the SPEARHEAD-1 trial, and next steps for research.

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.

Brad S. Kahl, MD, discusses personalizing frontline treatment in mantle cell lymphoma, clinical trials further examining BTK inhibitors, and research opportunities with CAR T-cell therapy.

Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study.

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

The addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow transplantation in up to 2 apheresis sessions vs G-CSF alone in patients with multiple myeloma, meeting the primary end point of the phase 3 GENESIS trial.

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

Nusayba Bagegni, MD, discusses prominent data that have emerged in early-stage and metastatic HER2-positive breast cancer.

Nusayba Bagegni, MD, discusses the safety profile of ado-trastuzumab emtansine in early-stage HER2-positive breast cancer.

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Brian Van Tine, MD, PhD, discusses what tazemetostat’s approval brings to the treatment landscape for patients with epithelioid sarcoma.

Brad S. Kahl, MD, outlines the available treatment options in indolent non-Hodgkin lymphoma, factors that may influence treatment selection, and promising agents on the horizon.

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.

Brian A. Van Tine, MD, PhD, discusses the results of a phase I study looking at the effects of ADP-A2M4 in patients with synovial sarcoma.

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

Physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $7.8 million grant from the National Cancer Institute to play a leading role in designing, conducting and enrolling patients in clinical trials through the NCI

Brian A. Van Tine, MD, PhD, discusses collaboration within the sarcoma field and the importance of clinical trials for advancing treatment.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses exciting data on the horizon in chronic lymphocytic lymphoma (CLL).

Stephen Oh, MD, PhD, discusses the use of ruxolitinib in patients with myelofibrosis and polycythemia vera, and emerging agents and next steps in the field of myeloproliferative neoplasms.